Jakarta, CNN Indonesia –
Recent studies reported vaksin Covid-19 Novavax has an efficacy of 51 percent against infections caused by the original coronavirus variant south Africa among people who are HIV-negative and and 43 percent in a group that includes HIV-positive people.
Several studies have shown the South African variant known as B.1.351 carries mutations that threaten the efficacy of the Covid-19 vaccine. Most vaccine manufacturers, including Novavax, are testing versions of their vaccines to protect against emerging variants.
Launch ReutersNovavax has released a post-hoc analysis in the New England Journal of Medicine along with full data from a trial in South Africa, which included nearly 2,700 volunteers who were not previously infected with the coronavirus.
In January 2021, studies demonstrated a 60.1 percent efficacy against Covid-19 symptoms in a trial in South Africa that looked at a mixture of the original virus and the South African variant among those who were HIV-negative. Efficacy was 49.4 percent among the mixed cohort of HIV positive and HIV negative participants.
The study also showed that previous infection with an earlier version of the virus did not reduce the risk of Covid-19 caused by the South African variant among people who got the placebo injection.
The mean age of the trial volunteers was 32 years. Most cases are mild to moderate.
The study did not provide data on the efficacy of the Novavax vaccine in preventing severe disease or hospitalization, one of the most important factors in determining vaccine usefulness.
“Most vaccines are less effective at preventing mild disease than at preventing severe disease; so this vaccine could be much more effective at preventing hospital admissions and deaths we don’t know yet,” said Peter English, consultant in infectious disease control and former chair of the British Medical Association’s. Public Health Medicine Committee.
The main aim of the trial is to test how the vaccine works in people who are HIV-negative, as well as those who are HIV-positive and are medically stable. Of those evaluated, 94 percent were HIV negative and 6 percent were HIV positive.
John Moore, a professor of microbiology and immunology at Weill Cornell Medical College who was not involved in the study said he was not surprised that efficacy was lower among volunteers with HIV, the virus that attacks the immune system.
(jps / DAL)
– .
